James O'Kelly

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Clin Invest 109:1091-9. 2002
  2. ncbi Vitamin D analogs and breast cancer
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Recent Results Cancer Res 164:333-48. 2003
  3. ncbi Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    J Steroid Biochem Mol Biol 100:107-16. 2006
  4. ncbi RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by
    Takashi Kumagai
    Departments of Medicine and Pathology, Center of Health of Science, University of California at Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Clin Cancer Res 10:1508-20. 2004
  5. ncbi Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation
    Sigal Tavor
    Division of Hematology Oncology, Cedars Sinai Medical Center, School of Medicine, UCLA, Los Angeles, California 90048, USA
    J Biol Chem 278:52651-9. 2003
  6. ncbi Cyr61 suppresses growth of human endometrial cancer cells
    Wenwen Chien
    Department of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 110 George Burns Rd, D5065, Los Angeles, CA 90048, USA
    J Biol Chem 279:53087-96. 2004
  7. ncbi Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Clin Cancer Res 10:1141-9. 2004
  8. ncbi Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
    Ido Wolf
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 30:1529-37. 2007
  9. ncbi Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells
    Akio Mori
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, CA 90048, USA
    Cancer Res 66:3222-9. 2006
  10. doi Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase
    Naoki Wakimoto
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, USA
    Cancer Res 68:6978-86. 2008

Detail Information

Publications106 found, 100 shown here

  1. pmc Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Clin Invest 109:1091-9. 2002
    ..The observed reduction in Th1 population in these mutant mice may be explained by a loss of macrophage IL-18 production or a suppression of STAT4 expression by activated splenocytes...
  2. ncbi Vitamin D analogs and breast cancer
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Recent Results Cancer Res 164:333-48. 2003
    ..Evidence from both in vitro and in vivo studies has demonstrated that vitamin D compounds can inhibit the growth of breast cancer cells, suggesting their therapeutic value in the treatment or prevention of this disease...
  3. ncbi Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    J Steroid Biochem Mol Biol 100:107-16. 2006
    ..Inhibition of the Akt-mTOR pathway represents a novel mechanism by which vitamin D3 analogs may modulate the expression and activity of proteins involved in cancer cell proliferation...
  4. ncbi RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by
    Takashi Kumagai
    Departments of Medicine and Pathology, Center of Health of Science, University of California at Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Clin Cancer Res 10:1508-20. 2004
    ..We, therefore, investigated these effects in vitro and in vivo either alone or in combination with other compounds...
  5. ncbi Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation
    Sigal Tavor
    Division of Hematology Oncology, Cedars Sinai Medical Center, School of Medicine, UCLA, Los Angeles, California 90048, USA
    J Biol Chem 278:52651-9. 2003
    ....
  6. ncbi Cyr61 suppresses growth of human endometrial cancer cells
    Wenwen Chien
    Department of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 110 George Burns Rd, D5065, Los Angeles, CA 90048, USA
    J Biol Chem 279:53087-96. 2004
    ..In summary, endometrial cancer cells have decreased expression of Cyr61 compared with normal endometrium, and this lowered expression may provide the transformed cells a growth advantage over their normal counterpart...
  7. ncbi Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Clin Cancer Res 10:1141-9. 2004
    ..Our purpose was to investigate the antiproliferative effects of the HDACIs [suberoyl anilide bishydroxamine, valproic acid (VPA), trichostatin A, and sodium butyrate] against six endometrial cancer cell lines...
  8. ncbi Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
    Ido Wolf
    Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 30:1529-37. 2007
    ..Our data suggest that HNK is a systemically available, non-toxic inhibitor of breast cancer growth and should be examined for clinical applications...
  9. ncbi Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells
    Akio Mori
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, CA 90048, USA
    Cancer Res 66:3222-9. 2006
    ..0006; capsaicin-treated versus vehicle-treated mice, respectively]. In summary, our data suggests that capsaicin, or a related analogue, may have a role in the management of prostate cancer...
  10. doi Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase
    Naoki Wakimoto
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, USA
    Cancer Res 68:6978-86. 2008
    ..Our studies provide evidence that the up-regulation of 15-PGDH induced by NSAIDs has the potential to inhibit growth of GBM, in part, by up-regulation of p21 possibly independent from COX-2 enzymatic function...
  11. ncbi Functional domains of CCN1 (Cyr61) regulate breast cancer progression
    James O'Kelly
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Oncol 33:59-67. 2008
    ....
  12. ncbi Vitamin D3 analogs stimulate hair growth in nude mice
    Vijaya Vegesna
    Cedars Sinai Medical Center University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Endocrinology 143:4389-96. 2002
    ..Vitamin D3 analogs seem to act on keratinocytes to initiate hair follicle cycling and stimulate hair growth in mice that otherwise do not grow hair...
  13. ncbi Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1
    Adrian F Gombart
    Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Blood 101:3265-73. 2003
    ..Furthermore, it indicates the importance of PU.1 in the cooperative activation of eosinophil granule genes...
  14. pmc A role for the clock gene per1 in prostate cancer
    Qi Cao
    Cedars Sinai Medical Center, Division of Hematology Oncology, University of California at Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Cancer Res 69:7619-25. 2009
    ....
  15. ncbi Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
    Sakura Sakajiri
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Exp Hematol 33:53-61. 2005
    ..In nude mice, SAHA significantly inhibited growth of a mantle cell lymphoma without major toxic side effects. In summary, HDACIs are promising therapeutic agents for human lymphoid cancers...
  16. ncbi Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo
    Vijaya Vegesna
    Cedars Sinai Medical Center UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Anticancer Res 23:283-9. 2003
    ..We compared in vivo the anti-cancer activity of three potent vitamin D3 analogs and 1,25(OH)2D3 at near to each of their maximal tolerated dose (MTD)...
  17. ncbi Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway
    Xiangjun Tong
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Oncogene 23:4847-55. 2004
    ..In this pathway, Cyr61 activated the beta-catenin/TCF4 complex, which promoted the expression of c-myc and the latter induced expression of p53, and p53 upregulated p21WAF1 and p130/RB2, resulting in growth arrest...
  18. ncbi 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Cancer Res 66:7818-23. 2006
    ..Our results indicate for the first time that 15-PGDH may be a novel tumor suppressor gene in breast cancer, and suggest that this enzyme can modulate the ER pathway...
  19. pmc Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells
    Takashi Kumagai
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Cancer 124:827-33. 2009
    ....
  20. ncbi PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells
    Takayuki Ikezoe
    Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Int J Oncol 23:1461-70. 2003
    ..Also, PC-SPES activated the JNK/c-Jun/AP-1 signal pathway resulting in growth arrest and apoptosis of prostate cancer cells...
  21. pmc Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma
    Tadayuki Akagi
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Int J Cancer 125:2349-59. 2009
    ..Thus, this SNP-chip analysis has identified several early cytogenetic events and novel candidate cancer-related genes that are potentially involved in the evolution of BE to EAC...
  22. ncbi Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells
    Wenwen Chien
    Division of Hematology Oncology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, D5022, Los Angeles, CA 90048, USA
    Mol Cancer Res 4:591-8. 2006
    ..Our data suggest that CTGF may behave as a secreted tumor suppressor protein in the normal lung, and its expression is suppressed in many NSCLCs...
  23. ncbi Protein partners of C/EBPepsilon
    Doris Y Chih
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, Calif 90048, USA
    Exp Hematol 32:1173-81. 2004
    ..Our results suggest heterodimeric partners of C/EBPepsilon modulate the function of C/EBPepsilon in mediating gene transcription during myelopoiesis...
  24. doi Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo
    Naoki Wakimoto
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles, School of Medicine, California 90048, USA
    Cancer Sci 99:1793-7. 2008
    ..g. taxol], vinca alkaloid [e.g. vincristine], and now CuB). Our in vitro and in vivo results suggest that CuB may be an effective, new approach for the treatment of ER-, Her2/neu amplified, and p53 mutant breast cancers...
  25. pmc Novel Gemini vitamin D(3) analogs have potent antitumor activity
    Tsuyako Saito
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    J Steroid Biochem Mol Biol 112:151-6. 2008
    ..05) more apoptosis than 1,25(OH)(2)D(3). In summary, these analogs have a unique structure resulting in extremely potent inhibition of clonal proliferation of various types of cancer cells, especially HL-60 cells...
  26. ncbi Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells
    Takayuki Ikezoe
    Division of Hematology Oncology, Cedars Sinai Medical Center, Pediatric Endocrinology, University of California at Los Angeles School of Medicine, USA
    Blood 104:237-42. 2004
    ..Taken together, these results indicate that IGFBP-3 has antiproliferative activity against myeloid leukemia cells; while it enhances signaling through RXR/RXR, it blunts signaling by activated RAR/RXR...
  27. ncbi CYR61: a new measure of lung cancer outcome
    Akio Mori
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Medical Center, University of California Los Angeles, School of Medicine, Los Angeles, USA
    Cancer Invest 25:738-41. 2007
    ..05). Taken together, Cyr61 appears to guard against metastatic disease because low expression is associated with more advanced disease; and therefore, expression levels of Cyr61 correlate with the prognosis of lung cancer...
  28. ncbi CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells
    Takayuki Ikezoe
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, California, USA
    Cancer Res 65:4762-8. 2005
    ..Taken together, forced expression of C/EBPdelta in cancer cells may be a promising therapeutic strategy...
  29. doi Adaptor protein Lnk associates with Tyr(568) in c-Kit
    Saskia Gueller
    Division of Hematology Oncology, Cedars Sinai Medical Center and UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles 90048, CA, USA
    Biochem J 415:241-5. 2008
    ..The identification of the binding site of Lnk to c-Kit will be useful to discover inhibitory molecules that prevent the binding of these two proteins, thus making haemopoietic cells more sensitive to growth factors...
  30. ncbi PC-SPES inhibits colon cancer growth in vitro and in vivo
    Sergio Huerta
    University of California Los Angeles UCLA Center for Human Nutrition, UCLA School of Medicine, 900 Veteran Avenue, 12 217 Warren Hall, Los Angeles, CA 90095, USA
    Cancer Res 62:5204-9. 2002
    ..This suggests that the components of this herbal mixture, either independently or in combination, acted in colon cancer, resulting in a drastic effect on tumor initiation and tumor progression...
  31. ncbi Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Breast Cancer Res Treat 105:139-55. 2007
    ..Thus, unmasking of epigenetic silencing in breast cancer enabled us to discover a large number of candidate tumor suppressor genes. Further analysis suggested a role of one of these genes, PTCH, in breast cancer tumorigenesis...
  32. ncbi Tumor suppressor genes in normal and malignant hematopoiesis
    Utz Krug
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, CA 90048, USA
    Oncogene 21:3475-95. 2002
    ..This review provides an overview of the current knowledge about the involvement of tumor suppressor genes in hematopoietic malignancies including those involved in cell cycle control, apoptosis and transcriptional control...
  33. ncbi Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines
    Takashi Kumagai
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Leuk Res 31:523-30. 2007
    ..HPLC analysis of S.B. showed it contains 21% baicalin and further studies confirmed it was the major anti-cancer component of S.B. Thus, Scutellaria baicalensis should be tested in clinical trials for these hematopoietic malignancies...
  34. doi Per2 is a C/EBP target gene implicated in myeloid leukemia
    Sigal Gery
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Integr Cancer Ther 8:317-20. 2009
    ..Overexpression of Per2 in hematopoietic cancer cell lines resulted in growth inhibition, cell cycle arrest, apoptosis and loss of clonogenic ability. These results support the emerging role of circadian genes in tumor suppression...
  35. ncbi HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo
    Takayuki Ikezoe
    Division of Hematology Oncology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, California, USA
    Cancer Res 64:7426-31. 2004
    ..In summary, combination therapy of ritonavir and anticancer drugs holds promise for the treatment of individuals with advanced, drug resistant cancers...
  36. ncbi Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors
    Carl W Miller
    Division of Hematology Oncology, Department of Medicine, UCLA School of Medicine, Cedars Sinai Research Institute, 8700 Beverly Blvd, Davis 5019, Los Angeles, CA 90048, USA
    Genes Chromosomes Cancer 33:17-21. 2002
    ..The occurrence of CHK2 mutations in sporadic cancers emphasizes the importance of the stress pathway which includes TP53...
  37. ncbi Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias
    Adrian F Gombart
    Cedars Sinai Medical Center, Burns and Allen Research Institute, Division of Hematology Oncology, University of California Los Angeles School of Medicine, 90048, USA
    Blood 99:1332-40. 2002
    ..These results suggest that mutation of C/EBPalpha is involved in specific subtypes of AML and in MDS, but may occur rarely in other types of leukemias or nonhematologic malignancies...
  38. ncbi Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells
    Takashi Kumagai
    Division of Hematology Oncology, UCLA School of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Int J Cancer 121:656-65. 2007
    ..SAHA is a novel, promising therapeutic agent for human pancreatic cancers...
  39. ncbi Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, Los Angeles, CA, USA
    Blood 100:3553-60. 2002
    ..Furthermore, this study provides evidence that in MDS, hematopoietic stem cells accumulate defects that prevent normal hematopoiesis...
  40. ncbi Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV
    Sven de Vos
    Division of Hematology Oncology and the Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 7059, USA
    Diagn Mol Pathol 12:35-43. 2003
    ..In summary, our microarray and QRT-PCR analyses identified several candidate genes whose expression increased when comparing normal follicular mantles with MCL and MCLBV, suggesting a potential pathogenic role in the evolution of MCL-BV...
  41. ncbi Repression of the TMEFF2 promoter by c-Myc
    Sigal Gery
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    J Mol Biol 328:977-83. 2003
    ..In light of the probable role of TMEFF2 in inhibiting cell growth, its suppression may contribute to the oncogenic properties of c-Myc...
  42. pmc Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis
    Wenwen Chien
    Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Int J Oncol 38:1741-7. 2011
    ..Deletion of the C-terminal cysteine knot domain, but not of any other domain-deleted mutants, abolished activities mediated by full-length CCN2. We have dissected the role of CCN2 in breast tumorigenesis on a structural basis...
  43. ncbi Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells
    Claudia I Muller
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Leuk Res 30:841-8. 2006
    ..These results indicate that G. lucidum extract has a profound activity against leukemia, lymphoma and multiple myeloma cells and may be a novel adjunctive therapy for the treatment of hematologic malignancies...
  44. ncbi Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3
    Adrian F Gombart
    Department of Medicine, Division of Hematology Oncology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    FASEB J 19:1067-77. 2005
    ..Our findings reveal a novel activity of 1,25-dihydroxyvitamin D3 and the VDR in regulation of primate innate immunity...
  45. ncbi Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon)
    Adrian F Gombart
    Division of Hematology Oncology, Cedars Sinai Medical Center, Burns and Allen Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
    Curr Opin Hematol 9:36-42. 2002
    ..Deficiencies in multiple myeloid lineages, in addition to neutrophils, indicate the importance of C/EBP(epsilon) in regulating important innate immune and inflammatory responses critical for host defense...
  46. pmc Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells
    Dhruva Kumar Mishra
    Division of Cancer Research and Training, Department of Medicine, Charles Drew University of Medicine and Science, Los Angeles, California 90059, USA
    Mol Cancer Ther 9:33-45. 2010
    ..In summary, our study identified candidate genes that are methylated in prostate cancer...
  47. doi Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia
    Soren Lehmann
    Department of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Cancer 112:1296-305. 2008
    ..Single nucleotide polymorphism (SNP) genomic array (SNP-chip) is a new tool that can detect copy number changes and uniparental disomy (UPD) over the entire genome with very high resolution...
  48. ncbi ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBPepsilon and C/EBPalpha
    Adrian F Gombart
    Cedars Sinai Medical Center, Division of Hematology Oncology, Davis Bldg 5019, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    J Leukoc Biol 81:1535-47. 2007
    ..We propose that ATF4 may regulate myeloid gene expression differentially by potentiating C/EBPepsilon but inhibiting C/EBPalpha-mediated transcriptional activation...
  49. pmc Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations
    Tadayuki Akagi
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA, USA
    Blood 113:1741-8. 2009
    ..Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in t(15;17) APL...
  50. doi Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array
    Norihiko Kawamata
    Hematology Oncology, Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, Calif, USA
    Exp Hematol 37:937-46. 2009
    ..This technique allows detection of genomic changes with higher resolution, including loss of heterozygosity without changes of gene dosage, so-called acquired uniparental disomy (aUPD)...
  51. pmc Impaired response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBPbeta-deficient hematopoietic cells
    Tadayuki Akagi
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Blood 111:2999-3004. 2008
    ..Our present results indicate that C/EBPbeta helps regulate survival of neutrophils, downstream of the granulocyte colony stimulating factor receptor...
  52. pmc SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
    Daniel Nowak
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, CA 90048, USA
    Blood 115:1049-53. 2010
    ..This may support a hypothesis of TKI-induced selection of subclones differentiating into immature B-cell progenitors as a mechanism of disease progression and evasion of TKI sensitivity...
  53. ncbi Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia
    Norihiko Kawamata
    Hematology Oncology, Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, CA 90048, USA
    Int J Oncol 34:1603-12. 2009
    ..In summary, additional genomic changes are very common events in ALL at relapse; whether these abnormalities are associated with resistance to treatment remains to clarified in further studies...
  54. pmc Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype
    Tadayuki Akagi
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Haematologica 94:213-23. 2009
    ..Here, we identified hidden genomic alterations and novel disease-related regions in normal karyotype acute myeloid leukemia/myelodysplastic syndrome samples...
  55. ncbi PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells
    Takayuki Ikezoe
    Division of Hematology Oncology and Thoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Int J Oncol 29:453-61. 2006
    ..PC-SPES might be useful in the adjuvant setting for the treatment of individuals with resected NSCLC as well as other types of cancer in which COX-2 is activated...
  56. ncbi Discovery of epigenetically masked tumor suppressor genes in endometrial cancer
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Cancer Res 3:261-9. 2005
    ..Our data suggest that C/ebpalpha and Tig1 function as tumor suppressor proteins in endometrial cancers and that their reexpression may be a therapeutic target...
  57. ncbi Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors
    Naoki Mori
    Department of Medicine, Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, USA
    Int J Hematol 77:259-62. 2003
    ..Sequence analysis and in vitro kinase assays showed that most of the mutations that disrupted interactions with p16(INK4) also knocked out the activity of CDK4. This result may explain the rareness of CDK4 mutations in human tumors...
  58. ncbi Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Exp Hematol 30:318-23. 2002
    ..The human insulin-like growth factor 2 (IGF2) gene was thought to be imprinted and expressed only from the paternal allele in normal tissue...
  59. ncbi Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Cancer 101:2760-70. 2004
    ..Histone deacetylase inhibitors (HDACIs) can inhibit proliferation, stimulate apoptosis, and induce cell cycle arrest in malignant cells...
  60. ncbi C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies
    Vijaya Vegesna
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Leuk Res 26:451-7. 2002
    ..The C/EBP-delta alteration in Raji was a missense mutation (A177G). These findings suggest that mutations of the C/EBP-beta, C/EBP-delta, PU.1, and AML1 rarely contribute to the development of hematopoietic or solid cancers...
  61. ncbi RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia
    Letetia C Jones
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Oncogene 23:7846-53. 2004
    ..Our results suggest that RARbeta2 acts as a tumor suppressor gene in MMM and that epigenetic changes are the most significant determinants of RARbeta2 gene activity in these patients...
  62. ncbi In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies
    Edward B Garon
    Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int J Cancer 121:675-82. 2007
    ..Therefore, nanoelectropulse therapy deserves further study as a potentially effective cancer therapy...
  63. ncbi TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells
    Sigal Gery
    Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, California, CA 90048, USA
    Oncogene 21:4739-46. 2002
    ....
  64. pmc BCL6 is critical for the development of a diverse primary B cell repertoire
    Cihangir Duy
    Childrens Hospital Los Angeles and Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA
    J Exp Med 207:1209-21. 2010
    ..We conclude that negative regulation of Arf by BCL6 is required for pre-B cell self-renewal and the formation of a diverse polyclonal B cell repertoire...
  65. ncbi 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia
    Takashi Kumagai
    Division of Hematology Oncology, University of California at Los Angeles School of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Cancer Res 65:2488-97. 2005
    ..The combination of both of these Food and Drug Administration-approved drugs should be considered for treatment of all-trans retinoic acid-resistant APL patients as well as those with other types of AML...
  66. ncbi Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways
    Dong Xie
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Cancer Res 64:1987-96. 2004
    ..Cyr61 appears to stimulate several signaling pathways in the development of gliomas...
  67. ncbi Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues
    Adrian F Gombart
    Cedars Sinai Medical Center, Department of Medicine, Division of Hematology Oncology, Burns and Allen Research Institute, David Geffen School of Medicine at UCLA, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    J Steroid Biochem Mol Biol 103:552-7. 2007
    ..The data suggest that regulation of CAMP by 1,25(OH)(2)D(3) is potentially important in a wide range of tissues...
  68. ncbi Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo
    Quang T Luong
    Department of Medicine and the Samuel Oschin Comprehensive Cancer Center, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Clin Cancer Res 12:5570-7. 2006
    ..The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), has multiple antitumor effects against a variety of human cancers...
  69. ncbi Effect of ligands of nuclear hormone receptors on sodium/iodide symporter expression and activity in breast cancer cells
    Sakae Tanosaki
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Breast Cancer Res Treat 79:335-45. 2003
    ....
  70. ncbi Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas
    Dong Xie
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California Los Angeles UCLA School of Medicine, Los Angeles, California 90048, USA
    Clin Cancer Res 10:2072-81. 2004
    ..These results suggest that CYR61 and CTGF may play a role in the progression of gliomas; their levels at diagnosis may have prognostic significance; and these proteins might serve as valuable targets for therapeutic intervention...
  71. pmc Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway
    Alexey M Chumakov
    Department of Medicine, Cedars Sinai Medical Center, University of California at Los Angeles, CA 90048, USA
    Blood 109:4209-19. 2007
    ..We suggest that interaction of the activated NFkappaB pathway and C/EBP-epsilon may be important in selective activation of a subset of C/EBP-epsilon-responsive genes...
  72. ncbi Aberrant expression of neutrophil and macrophage-related genes in a murine model for human neutrophil-specific granule deficiency
    Adrian F Gombart
    Cedars Sinai Medical Center, Division of Hematology Oncology, Burns and Allen Research Institute and David Geffen School of Medicine at University of California Los Angeles, USA
    J Leukoc Biol 78:1153-65. 2005
    ..In summary, dysregulation of numerous, novel C/EBPepsilon target genes impairs innate immune response and possibly other important biological processes mediated by neutrophils and macrophages...
  73. ncbi Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells
    Takashi Kumagai
    Division of Hematology Oncology, Department of Medicine, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, 90048, USA
    J Natl Cancer Inst 95:896-905. 2003
    ..We investigated the antitumor activity and mechanism of action of paricalcitol in vitro and in vivo...
  74. pmc Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells
    Talin Haritunians
    Division of Hematology Oncology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA 90048, USA
    Oncol Rep 20:1237-42. 2008
    ..LY573636, as shown before in solid tumors, is effective in hematopoietic cell lines as well. These data suggest the use of LY573636 alone or in combination with conventional chemotherapeutic regimens in hematopoietic malignancies...
  75. ncbi Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis
    Hiroshi Kawabata
    Division of Hematology Immunology, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Blood 105:376-81. 2005
    ..These results suggest that up-regulation of hepcidin expression by inflammatory stimuli is independent of TfR2 and that TfR2 is upstream of hepcidin in the regulatory pathway of body iron homeostasis...
  76. ncbi Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome
    H Phillip Koeffler
    Division of Hematology Oncology, Davis 5005, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Leuk Res 29:1259-62. 2005
    ..In summary, paricalcitol given as a single agent to MDS patients is therapeutically not very efficacious; further trials of the Vitamin D analog should be considered in combination with other approaches...
  77. ncbi Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene
    Hiroya Asou
    Department of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
    Genes Chromosomes Cancer 36:167-74. 2003
    ..The Kasumi-6 cell line can serve as a model to study the cellular and molecular biology of the non-t(8;21) M2 type of myeloid leukemia and can elucidate the role of mutated C/EBPalpha in leukemogenesis...
  78. ncbi PC-SPES decreases proliferation and induces differentiation and apoptosis of human acute myeloid leukemia cells
    Takayuki Ikezoe
    Department of Medicine, Kochi Medical School, Nankoku, Kochi 783 8505, Japan
    Int J Oncol 23:1203-11. 2003
    ..PC-SPES might be useful with ATRA for treatment of patients with acute promyelocytic leukemia (APL), and it could have a role in other types of cancers including MDS...
  79. ncbi Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells
    Takayuki Ikezoe
    Department of Internal Medicine, Kochi Medical School, Nankoku, Kochi 783 8505, Japan
    Int J Oncol 23:1187-93. 2003
    ..Oridonin may be a novel, adjunctive therapy for a large variety of malignancies and probably represents one of the major, active components of PC-SPES...
  80. ncbi Mutations in the retinoblastoma-related gene RB2/p130 in adult T-cell leukaemia/lymphoma
    Seisho Takeuchi
    Department of Internal Medicine, Kochi Medical School, Okohcho, Nankoku, Kochi 783 8505, Japan
    Leuk Lymphoma 44:699-701. 2003
    ..This is the first report describing mutation of the RB2/p130 gene in ATL, suggesting that RB2/p130 may be involved in the development of ATL, and may behave as a tumor suppressor gene in T lymphocytes...
  81. ncbi Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells
    Richard H Weisbart
    Department of Medicine, Division of Rheumatology, Veterans Affairs Greater Los Angeles Health Care System, Sepulveda, CA 91343, USA
    Cancer Lett 195:211-9. 2003
    ..Our results demonstrate the potential efficacy of antibody scFv fragments as a nuclear delivery system in cancer cells...
  82. ncbi Expression of bactericidal/permeability-increasing protein requires C/EBP epsilon
    Miyuki Tanaka
    Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan
    Int J Hematol 85:304-11. 2007
    ..Expression of BPI in human cord blood cells was increased by incubation with 10-7 MATRA for 48 hours. These results demonstrate the requirement for C/EBP epsilon in mediating BPI gene expression in myeloid cells in vitro and in vivo...
  83. ncbi Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
    Wolf Karsten Hofmann
    Department of Hematology, University Hospital, Theodor Stern Kai 7, 60596, Frankfurt Main, Germany
    Blood 102:659-61. 2003
    ..The findings suggest that the mutation exists in a very small subpopulation of leukemic cells at the beginning of STI571 therapy...
  84. ncbi Frameshift mutations in caspase-5 and other target genes in leukemia and lymphoma cell lines having microsatellite instability
    Seisho Takeuchi
    Department of Internal Medicine, Kochi Medical School, Okohcho, Nankoku 783 8505, Japan
    Leuk Res 27:359-61. 2003
    ..This is the first report that describes mutations of these genes in hematological malignancies. Mutations, presumably caused by an abnormality of the DNA repair genes, may be selected for during the establishment of cell lines...
  85. ncbi CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia
    Bao Tran H Truong
    Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco 94143 0128, USA
    Blood 101:1141-8. 2003
    ..Our results support the hypothesis that induction of C/EBP activity is a critical effect of tRA in APL. Furthermore, our findings suggest that targeted modulation of C/EBP activities could provide a new approach to therapy of AML...
  86. ncbi The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells
    Woo Hyun Park
    Cancer Research Institute and Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110 799, Korea
    Int J Oncol 20:533-42. 2002
    ..Taken together, these results suggest that treatment with both EB1089 and TGF-beta1 synergistically inhibits the proliferation of NCI-H929 cells through apoptosis...
  87. doi MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells
    Chie Nishioka
    Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783 8505, Japan
    Leuk Res 32:1382-92. 2008
    ..Taken together, MS-275 may be useful for treatment of individuals with leukemia possessing activating mutation of FLT3 gene...
  88. ncbi Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas
    Chuanbing Zang
    Division of Oncology Hematology, School of Medicine Charite, Humboldt University, Berlin, Germany
    J Neurooncol 65:107-18. 2003
    ..Therefore, we conclude that these ligands may possess adjuvant therapeutic potential for patients with glioblastoma...
  89. ncbi SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells
    Naoki Komatsu
    Department of Hematology Respiratory, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, 90048, USA
    Oncol Rep 15:187-91. 2006
    ..Protein assay by Western blot analysis showed that SAHA induced expression of p21WAF1. These results demonstrated that administration of SAHA may be a novel approach to the treatment of non-small cell lung cancer...
  90. ncbi Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways
    Takayuki Ikezoe
    Department of Hematology and Respiratory Medicine, KMS, Kochi Medical School, Nankoku, 783 8505 Kochi, Japan
    Mol Cancer Ther 4:578-86. 2005
    ..Taken together, oridonin might be useful as adjunctive therapy for individuals with lymphoid malignancies, including the lethal disease adult T-cell leukemia...
  91. ncbi Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways
    Yang Yang
    Department of Hematology and Respiratory Medicine, Kochi University, Okohcho, Nankoku, Kochi 783 8505, Japan
    Oncol Rep 15:1581-90. 2006
    ..Taken together, Zanthoxyli Fructus might be useful as an adjunctive therapeutic agent for the treatment of individuals with a variety of cancer types...
  92. ncbi The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells
    Jennifer Worch
    Department of Medicine, Hematology and Oncology, University of Munster, Domagkstr 3, 48129 Munster, Germany
    Oncogene 23:9162-72. 2004
    ..MNK1 plays a role in myeloid differentiation. These data suggest a role for MNK1 in the AML fusion protein-associated differentiation block...
  93. ncbi The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines
    Roberta Morosetti
    Division of Pediatric Oncology, Catholic University of Rome, 00168 Rome, Italy
    Int J Oncol 25:493-502. 2004
    ..By contrast, the modulation of differentiation-associated proteins by PGJ2, but not rosiglitazone, suggests that PGJ2 promotes differentiation of glioblastoma cells independently of PPARgamma activation...
  94. ncbi Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias
    Marina Konopleva
    Section of Molecular Hematology and Therapy and Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 3:1249-62. 2004
    ....
  95. ncbi ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib
    Yang Yang
    Department of Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100083, China
    Cancer Sci 97:1404-9. 2006
    ..The combination of ZD6474 and sunitinib should be investigated further...
  96. ncbi Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells
    Takayuki Ikezoe
    Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi 783 8505, Japan
    Leuk Res 31:673-82. 2007
    ..Taken together, longitudinal inhibition of PI3K/Akt/mTOR signaling represents a promising treatment strategy for individuals with adult T-cell leukemia...
  97. ncbi The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling
    Takayuki Ikezoe
    Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi 783 8505, Japan
    Mol Cancer Ther 5:2522-30. 2006
    ..Taken together, sunitinib may be useful for treatment of individuals with leukemias possessing activation mutation of tyrosine kinase, and the combination of sunitinib and RAD001 represents a promising novel treatment strategy...
  98. ncbi Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation
    Paulette Mhawech
    Department of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
    Mod Pathol 18:340-8. 2005
    ..Loss of 14-3-3sigma expression due to promoter hypermethylation may represent the most frequent molecular aberration in ovarian, endometrial and prostate adenocarcinomas...
  99. ncbi Identification of interaction partners and substrates of the cyclin A1-CDK2 complex
    Sven Diederichs
    Department of Medicine, Hematology Oncology, University of Munster, D 48129 Munster, Germany
    J Biol Chem 279:33727-41. 2004
    ..Thereby, we establish a new basis for future functional analyses of cyclin A1. We provide evidence that the cyclin A1-CDK2 complex plays a role in several signaling pathways important for cell cycle control and meiosis...
  100. ncbi HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24
    Takayuki Ikezoe
    Department of Hematology and Respiratory Disease, KMS, Kochi University, Okohcho, Kochi 783 8505, Japan
    Leuk Res 30:1005-11. 2006
    ..Taken together, inhibition of CYP24 might open a new paradigm for therapy using Vitamin D compounds...
  101. ncbi AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
    Jing Yang
    Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi, Japan
    Blood 110:2034-40. 2007
    ..Taken together, AZD1152 is a promising new agent for treatment of individuals with leukemia. The combined administration of AZD1152 and conventional chemotherapeutic agent to patients with leukemia warrants further investigation...